Ann: Voluntary Suspension, page-358

Tomorrow could well be the day and by flicking through previous presentations and announcements, I expect nothing less than a success.

This is not a red or black biotech play, many during this period have forgotten the extensive Australian trials and the names ResApp have been associated with. Even if one disease bucket comes up with subpar results, ResApp can still apply for all the other diseases they have collected and still commercialise a product which every Telehealth company would integrate with from day 1.

But ResApp are not pitching themselves solely as a Telehealth product, they want to be the gold standard in modern respiratory diagnosis. Which is why MGH have extended their trial and why we still have domestic trials ongoing, to collect as much data as possible.

It can be argued ResApp have been a marketing company to date - I generally disagree although its now time to deliver the goods.